“Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients With Moderate to Severe Plaque Psoriasis: Post-Hoc Results from Five Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s303, https://doi.org/10.25251/skin.8.supp.303.